NewsRoom Articles - Page 88 of 89

WednesdayAug 21, 2019 9:00 am

Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector

BioMedWire Editorial Coverage: Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) has completed key steps in its overall strategy to expand its clinical development programs and bring Oncoprex(TM) immunogene therapy, its lead drug candidate, to commercialization. Over the past five years, Amgen Inc. (NASDAQ: AMGN) has invested nearly $19 billion in R&D and, as a result, is now advancing a record number of clinical assets. Biogen Inc. (NASDAQ: BIIB) has added four new programs…

WednesdayMay 29, 2019 11:08 am

Genprex Inc. (NASDAQ: GNPX) Hires Top Pharmaceutical Branding Agency to Oversee Drug Naming Process for Lead Drug Candidate

Genprex, a clinical stage gene therapy company, will be utilizing the services of a leading pharmaceutical branding agency to oversee the naming process of its lead drug candidate, Oncoprex Addison Whitney has over 28 years of experience in the market, guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps involved in the name approval process Oncoprex is an innovative immunogene therapy targeting non-small cell lung cancer Genprex Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, recently reported that it has retained the services of leading pharmaceutical branding agency Addison Whitney to assist with the naming…

WednesdayMay 29, 2019 9:00 am

Biotechs That Successfully Combat Cancer Could See Blockbuster Returns

BioMedWire Editorial Coverage: Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is leveraging its patented technology platform to deliver powerful tumor-suppressing genes directly into cancer cells. Calithera Biosciences Inc. (NASDAQ: CALA) is looking for cures for cancer and other life-threatening diseases by discovering, developing and commercializing novel, small-molecule drugs that target tumor and immune cell metabolism. Adaptimmune Therapeutics plc (NASDAQ: ADAP) is developing novel cancer immunotherapy products for cancer patients by engineering T-cells to target and destroy cancer. Agenus…

TuesdayMay 28, 2019 12:10 pm

Genprex Inc. (NASDAQ: GNPX) Pioneering an Innovative Cancer Therapy, Preclinical Data Shows Positive Results

Gene therapy could help overcome barriers that currently stand in the way of a cure for cancer Genprex is developing innovative, gene-based approaches toward the treatment of cancer, specifically non-small cell lung cancer Clinical trials so far have yielded encouraging data regarding the efficacy and safety of the company’s product candidate, Oncoprex Gene therapy could potentially advance the creation and delivery of effective cancer treatments in the years to come. Various companies are leading the way, and pioneers such as Genprex Inc. (NASDAQ: GNPX) are pushing for the introduction of innovative and targeted therapies that have the potential to help…

WednesdayMay 08, 2019 11:24 am

Genprex Inc. (NASDAQ: GNPX) Aims to Reprogram the Course of Cancer with Gene Therapy Approach

Preclinical and clinical data indicate that Oncoprex immunogene therapy may be effective alone or in combination with targeted small molecule therapies; pre-clinical data also indicate potential effectiveness in combination with immunotherapies Lung cancer is the second-most common cancer and the leading cause of cancer deaths worldwide Genprex holds an exclusive license to more than 30 issued patents and several pending applications covering its platform technologies, including patents covering the therapeutic use of the TUSC2 tumor suppressor gene The value of the global immunotherapy drugs market is expected to surpass $385 billion by 2025, recording a CAGR of more than 14…

TuesdayMay 07, 2019 9:00 am

New Gene Therapies Hold Out Promise for Patients

BioMedWire Editorial Coverage: Gene therapies are gaining growing attention within the medical sector. Gene therapies help restore or replace the body’s damaged or missing genes. Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die. Gene therapies are also being developed for ailments such as migraines, skin conditions and hemophilia. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is developing gene therapies for the treatment of cancer, including its initial drug candidate, Oncoprex(TM) immunogene therapy. Spark Therapeutics Inc. (NASDAQ: ONCE) is tackling hereditary diseases through treatments that augment, suppress or replace mutated genes. Dyadic International Inc. (OTCQX: DYAI)…

ThursdayApr 18, 2019 11:44 am

Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data on Non-Small Cell Lung Cancer Treatment

Genprex’s collaborators at MD Anderson reported positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody for the treatment of non-small cell lung cancer The TUSC2 gene, a tumor suppressor gene, is the active agent in Genprex’s Oncoprex immunogene therapy, the company’s lead drug candidate for the treatment of lung cancer In combination with pembrolizumab, the TUSC2 gene significantly slowed tumor growth in mice with human immune cells Lung cancer ranks among the malignancies that are expected to increase the most in the coming years, especially among women; immunotherapy solutions may provide an effective option for…

WednesdayApr 10, 2019 9:00 am

Potential Blockbuster Gene Therapy Programs to Watch in 2019

BioMedWire Editorial Coverage: Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs underway looking to cure the incurable FDA expects 200 new gene and cell therapy INDs in next two years Genprex — and its initial product candidate Oncoprex — is pioneering a new approach to treating cancer. Built on decades of scientific research and innovation, gene therapy is the next frontier of medicine, determined to provide remedies for previously untreatable diseases…

WednesdayMar 27, 2019 9:00 am

Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy

BioMedWire Editorial Coverage: Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer. Gene therapies are being developed to more effectively target the treatment of cancer. Non-small cell lung cancer (NCSLC) is the leading cause of cancer death. Genprex Inc. is advancing Oncoprex, shown to benefit lung cancer patients in early trials. A multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is working to…

MondayMar 25, 2019 11:18 am

Genprex Inc. (NASDAQ: GNPX) is “One to Watch”

Lung cancer is one of the most prevalent and deadly cancers worldwide. Genprex aims to develop cutting-edge gene therapies to improve outcomes, which have not changed significantly in the past 25 years despite radical advances in drug development and novel therapeutic standards. Genprex holds a portfolio of 30 issued and two pending patents covering technologies and targeted molecular therapies, all exclusively licensed from University of Texas MD Anderson Cancer Center. Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who otherwise would not benefit from these important…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050